External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

High levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in breast cancer tissue extracts have been associated with rapid disease progression. In these studies, different enzyme-linked immunosorbent assay (ELISA) kits have been applied for the quan...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1998-12, Vol.78 (11), p.1434-1441
Main Authors: Sweep, CGJ, Geurts-Moespot, J, Grebenschikov, N, de Witte, JH, Heuvel, JJTM, Schmitt, M, Duffy, MJ, Jänicke, F, Kramer, MD, Foekens, JA, Brünner, N, Brugal, G, Pedersen, AN, Benraad, ThJ
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - chemistry
Cancer Research
Drug Resistance
Enzyme-Linked Immunosorbent Assay - methods
Enzyme-Linked Immunosorbent Assay - standards
Epidemiology
Europe
experimental-oncology
Female
Genital system. Mammary gland
Humans
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Mice
Mice, Nude
Molecular Medicine
Neoplasm Proteins - analysis
Oncology
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Plasminogen Activator Inhibitor 1 - analysis
Quality Control
Reagent Kits, Diagnostic - standards
Reference Values
Urokinase-Type Plasminogen Activator - analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in breast cancer tissue extracts have been associated with rapid disease progression. In these studies, different enzyme-linked immunosorbent assay (ELISA) kits have been applied for the quantification, and consequently the ranges of uPA and PAI-1 levels reported differ considerably. Therefore, the Receptor and Biomarker Study Group (RBSG) of the European Organization for Research and Treatment of Cancer (EORTC) and a consortium of the BIOMED-1 project 'Clinical Relevance of Proteases in Tumor Invasion and Metastasis' initiated three collaborative between-laboratory assessment trials aimed at controlling uPA and PAI-1 antigen analyses. For this purpose, two control preparations were produced from different sources: pooled human breast cancer specimens (QC-240893) and human breast cancer xenografts raised in nude mice (QC-101094). The lyophilized preparations were stable for prolonged times (at least 3 and 27 months respectively) at 4 degrees C. Furthermore, a good parallelism following dilution was found for uPA and PAI-1. The data from QC trial no. 1 clearly indicated that acceptable between-laboratory coefficients of variation (CVs) for uPA (
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1998.704